It is possible that the failure to identify positive results was due to an early change in delivery device to a newer one not yet tested in AD
Heres the research physicians should know: Liew et al., 2014 (JAMA Pediatrics) risk ADHD/hyperkinetic disorders Brandlistuen et al., 2013 (IJE, MoBa Norway) Long-term use psychomotor & behavioral problems Avella-Garca et al., 2016 (IJE, Spain) ASD symptoms in boys, attention issues in both sexes Bornehag et al., 2018 (EHP, Sweden) Language delay in girls Ji et al., 2019 (JAMA Psychiatry) Cord blood biomarkers dose-response risk for ADHD & ASD Baker et al., 2020 (JAMA Pediatrics) Meconium biomarkers ADHD risk & altered brain connectivity Sznajder et al., 2022 (PLOS One) Use linked with neurobehavioral problems at 3 years Woodbury et al., 2024 (Pediatric Research / JDBP) Dose-response
Phase Weeks 3+ (standard) Daily dose 100 mg once daily Notes The most common research community target dose
Introduction The recommended dose of glutathione depends on the delivery method: oral doses range from 2501,000 mg daily, liposomal forms from 100500 mg , sublingual from 100300 mg , and intravenous infusions from 6001,200 mg
Values below 1.0 indicate risk reduction
Essen Sie reichlich Vitamin C und E Vitamin C und E sind wichtige Antioxidantien, die zusammen mit Glutathion die Zellen vor oxidativen Schden schtzen
